MAPT and Alzheimer disease: Therefore, specific γ-secretase inhibitors, modulators that particularly reduce of Aβ42 production, or stabilizers that produce longer Aβ peptides (≥42) [15], in combination with other therapies that target hyperphosphorylated tau or neuroinflammation, may be used to effectively slow down the pathological progression and development of AD from early to later stages.